Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
2.
Prostaglandins ; 47(1): 17-30, 1994 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-8140259

RESUMO

CI-986 is a potent inhibitor of 5-lipoxygenase and cyclooxygenase pathway product biosynthesis from rat basophilic leukemia (RBL) cells. Because metabolites from these pathways have proinflammatory properties, CI-986 was evaluated in several acute and chronic models of inflammation and hyperalgesia. The compound inhibited swelling in the carrageenan footpad edema, Mycobacterium foot-pad edema and adjuvant arthritis models of inflammation with ID40 values of 1.0, 7.7., and 7.2 mg/kg, respectively. It was roughly equivalent in potency to the standard selective cyclooxygenase inhibitor, naproxen (ID40 = 0.7, 6.3, and 3.8 mg/kg, respectively). CI-986 was also evaluated in the acetic acid induced writhing hyperalgesia assay (ID50 = 0.23 mg/kg) and was approximately equipotent with indomethacin (ID50 = 0.87 mg/kg). Although the effects of CI-986 were similar to those of standard nonsteroidal antiinflammatory drugs (NSAIDs) in the inflammation models, its gastrointestinal profile was unique. CI-986 caused no gastrointestinal irritation at doses up to 200 mg/kg in acute and chronic studies. In contrast, standard NSAIDs caused ulcers at doses of 3.7-37 mg/kg after a single dose. Moreover, CI-986 inhibited the release of LTC4 and PGE2 by gastric mucosa and reduced mucosal and vascular damage induced by oral administration of absolute ethanol to rats. These results indicate that CI-986 is a potent nonulcerogenic antiinflammatory agent with novel pharmacologic properties.


Assuntos
Anti-Inflamatórios não Esteroides/uso terapêutico , Ácido Araquidônico/metabolismo , Gastrite/tratamento farmacológico , Inflamação/tratamento farmacológico , Dor/tratamento farmacológico , Tiadiazóis/uso terapêutico , Animais , Artrite Experimental/tratamento farmacológico , Inibidores de Ciclo-Oxigenase/uso terapêutico , Dinoprosta/antagonistas & inibidores , Dinoprosta/biossíntese , Modelos Animais de Doenças , Etanol , Feminino , Gastrite/induzido quimicamente , Inflamação/metabolismo , Leucotrieno B4/antagonistas & inibidores , Leucotrieno B4/biossíntese , Inibidores de Lipoxigenase/uso terapêutico , Masculino , Camundongos , Ratos , Ratos Wistar , Células Tumorais Cultivadas
3.
J Med Chem ; 36(8): 1090-9, 1993 Apr 16.
Artigo em Inglês | MEDLINE | ID: mdl-8478906

RESUMO

To discover dual inhibitors of 5-lipoxygenase (LO) and cyclooxygenase (CO) with improved pharmacokinetic properties, we have designed and synthesized series of 1,2,4-triazole, 1,3,4-oxadiazole, and 1,3,4-thiadiazole di-tert-butylphenol derivatives which exhibit a wide range of log P (2.3 to > 4) and pKa (5.5-12) values. From this work 5-[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]-1,3,4-thiadiazole-2(3H)- thione, choline salt (12a, CI-986) was found to be a potent inhibitor of 5-LO (IC50 = 2.8 microM) and CO (IC50 = 0.8 microM), orally active in rat models of inflammation and nonulcerogenic.


Assuntos
Anti-Inflamatórios não Esteroides/síntese química , Inibidores de Ciclo-Oxigenase/síntese química , Imidazóis/síntese química , Oxidiazóis/síntese química , Tiadiazóis/síntese química , Triazóis/síntese química , Animais , Anti-Inflamatórios , Anti-Inflamatórios não Esteroides/química , Inibidores de Ciclo-Oxigenase/química , Inibidores de Ciclo-Oxigenase/farmacologia , Imidazóis/química , Imidazóis/farmacologia , Inibidores de Lipoxigenase , Masculino , Oxidiazóis/química , Oxidiazóis/farmacologia , Ratos , Ratos Wistar , Tiadiazóis/química , Tiadiazóis/farmacologia , Triazóis/química , Triazóis/farmacologia
4.
J Med Chem ; 35(5): 958-65, 1992 Mar 06.
Artigo em Inglês | MEDLINE | ID: mdl-1372359

RESUMO

The synthesis and antiallergic activity of a series of novel benzothiophene-, benzofuran-, and naphthalenecarboxamidotetrazoles are described. A number of the compounds inhibit the release of histamine from anti-IgE stimulated basophils obtained from allergic donors. Optimal inhibition is exhibited in benzothiophenes with a 3-alkoxy substituent in combination with a 5-methoxy, 6-methoxy, or a 5,6-dimethoxy group. Compound 13c (CI-959) also inhibited respiratory burst of human neutrophils and the release of mediators from anti-IgE-stimulated human chopped lung.


Assuntos
Benzofuranos/síntese química , Antagonistas dos Receptores Histamínicos/síntese química , Naftalenos/síntese química , Tetrazóis/síntese química , Tiofenos/síntese química , Anticorpos Anti-Idiotípicos/imunologia , Basófilos/efeitos dos fármacos , Basófilos/imunologia , Basófilos/fisiologia , Benzofuranos/farmacologia , Eosinófilos/efeitos dos fármacos , Eosinófilos/fisiologia , Antagonistas dos Receptores Histamínicos/farmacologia , Liberação de Histamina/efeitos dos fármacos , Humanos , Hipersensibilidade/sangue , Imunoglobulina E/imunologia , Pulmão/efeitos dos fármacos , Pulmão/metabolismo , Estrutura Molecular , Naftalenos/farmacologia , Neutrófilos/efeitos dos fármacos , Neutrófilos/fisiologia , Explosão Respiratória/efeitos dos fármacos , Relação Estrutura-Atividade , Tetrazóis/farmacologia , Tiofenos/farmacologia
5.
J Med Chem ; 34(7): 2186-94, 1991 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-1712394

RESUMO

The synthesis and antiallergic activity of a series of novel thiophene-, pyrrole-, furan-, and benzenecarboxamidotetrazoles are described. A number of compounds inhibit the release of histamine from anti-IgE-stimulated human basophils. Optimal inhibition is exhibited in compounds with a 3-alkoxy, a 4-halo, and a 5-methyl, 5-methoxy, or 5-bromo on a thiophene-2-carboxamidotetrazole.


Assuntos
Derivados de Benzeno/síntese química , Antagonistas dos Receptores Histamínicos H1/síntese química , Pirróis/síntese química , Tetrazóis/síntese química , Tiofenos/síntese química , Basófilos/efeitos dos fármacos , Basófilos/metabolismo , Derivados de Benzeno/farmacologia , Fenômenos Químicos , Química , Antagonistas dos Receptores Histamínicos H1/farmacologia , Liberação de Histamina/efeitos dos fármacos , Humanos , Pirróis/farmacologia , Relação Estrutura-Atividade , Tetrazóis/farmacologia , Tiofenos/farmacologia
6.
J Med Chem ; 28(10): 1543-7, 1985 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-4045930

RESUMO

The antimicrobial and cytotoxic properties of a series of 9,10-dihydrophenanthrenes structurally related to juncusol (1a), a postulated phytoalexin with confirmed cytotoxic properties, are detailed. Two simple 9,10-dihydrophenanthrenes, 2,7-dihydroxy-3,8-dimethyl-9,10-dihydrophenanthrene (2h, desvinyljuncusol) and 2-hydroxy-3-methyl-9,10-dihydrophenanthrene (3h), were found to possess in vitro antimicrobial activity comparable with that of the natural product. Two 9,10-dihydrophenanthrenes substituted with quaternary ammonium salts, 2d and 3d, each containing a reactive benzylic dimethyl[(phenylthio)methyl]ammonio group, were found to be 10-20 times more potent than juncusol (1a). Confirmed in vitro cytotoxic activity that parallels antimicrobial activity was found for juncusol (1a), desvinyljuncusol (2h), 2-hydroxy-3-methyl-9,10-dihydrophenanthrene (3h), and the quaternary dimethyl[(phenylthio)methyl]ammonium salts 2d and 3d in a human lymphoblastic leukemia cell culture (CCRF-CEM, IC50 = nt, 9.3, nt, 0.9 and 1.4 microgram/mL, respectively), B-16 mouse melanoma cell culture (IC50 = 12.5, 17.5, 27.7, 0.3, and 0.5 microgram/mL, respectively), and L-1210 mouse lymphocytic leukemia cell culture (IC50 = 13.8, 10.2, 24.5, 1.3, and 3.7 micrograms/mL, respectively). The comparable potency and spectrum of activity of juncusol (1a), desvinyljuncusol (2h), and 2-hydroxy-3-methyl-9,10-dihydrophenanthrene (3h) suggest that the agents are acting as simple phenols in exerting their antimicrobial and cytotoxic effects.


Assuntos
Antibacterianos , Antineoplásicos Fitogênicos , Fenantrenos/farmacologia , Animais , Bactérias/efeitos dos fármacos , Sobrevivência Celular/efeitos dos fármacos , Células Cultivadas , Camundongos , Testes de Sensibilidade Microbiana , Neoplasias Experimentais/tratamento farmacológico , Fenantrenos/uso terapêutico , Relação Estrutura-Atividade
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...